Put companies on watchlist
clearvise AG
ISIN: DE000A1EWXA4
WKN: A1EWXA
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

clearvise AG · ISIN: DE000A1EWXA4 · EQS - Analysts (66 News)
Country: Germany · Primary market: Germany · EQS NID: 18953
21 February 2024 11:46AM

Buy


Original-Research: clearvise AG - von First Berlin Equity Research GmbH

Einstufung von First Berlin Equity Research GmbH zu clearvise AG

Unternehmen: clearvise AG
ISIN: DE000A1EWXA4

Anlass der Studie: Update
Empfehlung: Buy
seit: 21.02.2024
Kursziel: 3,20 Euro
Kursziel auf Sicht von: 12 Monaten
Letzte Ratingänderung: 12.04.2021: Hochstufung von Hinzufügen auf Kaufen Analyst: Dr. Karsten von Blumenthal

First Berlin Equity Research hat ein Research Update zu clearvise AG (ISIN: DE000A1EWXA4) veröffentlicht. Analyst Dr. Karsten von Blumenthal bestätigt seine BUY-Empfehlung und senkt das Kursziel von EUR 3,30 auf EUR 3,20.

Zusammenfassung:
clearvise hat ihre 0,8 MW-Biogasanlage verkauft und sich damit aus dem Biogasgeschäft zurückgezogen. Wir begrüßen diese Portfoliobereinigung, da der komplexe Biogasanlagenbetrieb inklusive Substratbeschaffung Ressourcen gebunden hat, die nunmehr für das Kerngeschäft, den Betrieb von Wind- und PV-Anlagen, frei werden. Außerdem stellt clearvise ihren größten Solarpark Klettwitz-Nord (90 MW) auf dynamische Einspeisung um, was eine zusätzliche Einspeisung von ca. 1.400 MWh p.a. ermöglicht. 2023 steigerte das Unternehmen die Stromproduktion um 8% J/J auf 534 GWh. Damit liegt clearvise genau in der Mitte der Guidance von 513 GWh - 555 GWh und über unserer Schätzung von 515 GWh. Wir berücksichtigen die Portfoliooptimierungen und das Stromproduktionsergebnis in unseren Schätzungen. Ein aktualisiertes DCF-Modell ergibt ein neues Kursziel von €3,20 (bisher: €3,30). Wir bekräftigen unsere Kaufempfehlung.

First Berlin Equity Research has published a research update on clearvise AG (ISIN: DE000A1EWXA4). Analyst Dr. Karsten von Blumenthal reiterated his BUY rating and decreased the price target from EUR 3.30 to EUR 3.20.

Abstract:
clearvise has sold its 0.8 MW biogas plant and has thus withdrawn from the biogas business. We welcome this portfolio streamlining as the complex biogas plant operation, including substrate procurement, has tied up resources that will now be freed up for the core business, the operation of wind and PV plants. In addition, clearvise is converting its largest solar park Klettwitz-Nord (90 MW) to dynamic feed-in, which will enable an additional feed-in of approx. 1,400 MWh p.a. In 2023, the company increased electricity production by 8% y/y to 534 GWh. This puts clearvise right in the middle of guidance of 513 GWh - 555 GWh and above our forecast of 515 GWh. We take into account the portfolio optimisations and the electricity production result in our estimates. An updated DCF model results in a new price target of €3.20 (previously: €3.30). We reiterate our Buy recommendation.

Bezüglich der Pflichtangaben gem. §85 Abs. 1 S. 1 WpHG und des Haftungsausschlusses siehe die vollständige Analyse.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/28953.pdf

Kontakt für Rückfragen
First Berlin Equity Research GmbH
Herr Gaurav Tiwari
Tel.: +49 (0)30 809 39 686
web: www.firstberlin.com
E-Mail: g.tiwari@firstberlin.com

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

Visual performance / price development - clearvise AG
Smart analysis and research tools can be found here.
MIC: XFRA

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.